Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia

202020 citationsJournal Articlegold Open Access

Authors

Our data support consideration of the application of ARQ 531 in combination trials for AML targeting higher drug concentrations in vivo.

Good health and well-being

Published in: Journal of Hematology & Oncology

Volume 13, Issue 1, pp. 8-8

Field-Weighted Citation Impact: 2.15